Search

• GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD

  Media

  GSK announces positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab) in adults with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd/

  First published: 06 September 2024

• GSK and Zhifei revise and extend strategic vaccine collaboration in China

  Media

  Shingrix collaboration extended to 2034

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-zhifei-revise-and-extend-strategic-vaccine-collaboration-in-china/

  First published: 05 December 2024

• US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD

  Media

  Nucala could be the first approved biologic with monthly dosing for patients with COPD

  https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd/

  First published: 09 December 2024

• Jemperli (dostarlimab) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer

  Media

  Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab.

  https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/

  First published: 16 December 2024

• European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

  Media

  Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases.

  https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 20 January 2025

• Nucala (mepolizumab) application for COPD accepted for review in China

  Media

  Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

  https://www.gsk.com/en-gb/media/press-releases/nucala-application-for-copd-accepted-for-review-in-china/

  First published: 20 February 2025

• GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency

  Media

  Nucala (mepolizumab) could be the first biologic with monthly dosing for patients with COPD, if approved

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-application-to-expand-use-of-nucala-for-the-treatment-of-copd-accepted-for-review-by-the-ema/

  First published: 24 March 2025

• GSK profiles innovative R&D portfolio to investors

  Media

  40 potential new medicines and vaccines offer opportunity to drive long-term performance and deliver new benefits to patients and consumers

  https://www.gsk.com/en-gb/media/press-releases/gsk-profiles-innovative-rd-portfolio-to-investors/

  First published: 03 November 2015

• GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) administered subcutaneously in patients with systemic lupus erythematosus

  Media

  GSK announces positive results from phase III BLISS-SC study of Benlysta® (belimumab) in patients with systemic lupus erythematosus

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-bliss-sc-study-of-benlysta-belimumab-administered-subcutaneously-in-patients-with-systemic-lupus-erythematosus/

  First published: 07 November 2015

• FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

  Media

  FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer

  https://www.gsk.com/en-gb/media/press-releases/fda-grants-accelerated-approval-for-gsk-s-jemperli-dostarlimab-gxly-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer/

  First published: 22 April 2021